Alnylam Pharmaceuticals Other Commercial Liabilities decreased by 12.4% to $946.49M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $704.17M to $946.49M. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows an upward trend with a 24.9% CAGR.
commercial_liabilities_other| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $341.19M | $388.58M | $395.17M | $355.94M | $421.24M | $510.58M | $545.46M | $508.60M | $598.53M | $713.09M | $713.01M | $698.87M | $808.64M | $946.17M | $793.69M | $704.17M | $918.97M | $1.15B | $1.08B | $946.49M |
| QoQ Change | — | +13.9% | +1.7% | -9.9% | +18.3% | +21.2% | +6.8% | -6.8% | +17.7% | +19.1% | -0.0% | -2.0% | +15.7% | +17.0% | -16.1% | -11.3% | +30.5% | +25.5% | -6.4% | -12.4% |
| YoY Change | — | — | — | — | +23.5% | +31.4% | +38.0% | +42.9% | +42.1% | +39.7% | +30.7% | +37.4% | +35.1% | +32.7% | +11.3% | +0.8% | +13.6% | +21.9% | +36.1% | +34.4% |